USA-based Provectus Pharmaceuticals says it has completed patient dosing in a Phase I assessment of its anticancer agent Provecta (PV-10), in the treatment of stage III/IV metastatic melanoma.
Provectus' chief executive, Craig Dees, explained that successful dosing represents the achievement of the trial's primary safety goals, adding that, "while it will be several months before final follow-up is completed for the last patient, Provecta was generally well-tolerated by all 20 patients with minimal side effects." Dr Dees went on to say that interim analysis of data from the first 11 patients had indicated that tumor response rate was higher than that achieved by the standard treatment.
Provectus added that it expects to release detailed results from the trial throughout the year as patient follow up is completed. The firm said that the drug is being examined as a treatment for cancers of the breast and liver.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze